General Electric (GE) announced on Monday, Feb. 25, that it has entered into a definitive agreement to sell its biopharma business to Danaher Corporation for $21.4 billion. This could significantly impact the company’s plans for an initial public offering (IPO) for GE Healthcare.
General Electric (GE) announced on Monday, Feb. 25, that it has entered into a definitive agreement to sell its biopharma business to Danaher Corporation for $21.4 billion. This could significantly impact the company’s plans for an initial public offering (IPO) for GE Healthcare.